



Programma sempre
aggiornato su
www.eoc.ch/formazioni

Istituto Oncologico della Svizzera Italiana

Oncolunch & Revisione Blau-Rotbuch IOSI 2023

Gli eventi si terranno in modalità online webinar e in presenza all'Auditorium dell'Ospedale Regionale di Bellinzona e Valli - Bellinzona.

11 gennaio

08h15 - 08h50
09h00 - 10h00

Highlights Prostate Cancers

Incontro clinico-patologico
Oncolunch

Prof. Dr. med. Karim Fizazi, Oncology Professor at the University of Paris-Saclay in Gustave Roussy Villejuif Cedex, France

Dr. Alison Tree, Consultant Clinical Oncologist MBBS BSc FRCR MD(Res), The Royal Marsden in Sutton, Surrey, United Kingdom

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

8 febbraio

08h15 - 08h50
09h00 - 10h00

Highlights Head and Neck Cancers

Incontro clinico-patologico
Oncolunch

Prof. Dr. Laura Deborah Locati, Associate Professor of Medical Oncology at the University of Pavia, Chief of Translational Oncology at IRCCS ICS Maugeri in Pavia, Italy

PD Dr. med. Panagiotis Balermipas, Coordinator Head and Neck Cancer Center, Comprehensive Cancer Center Zurich, Head Doctor, Department of Radiation Oncology, University Hospital Zurich USZ, Switzerland

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

8 marzo

08h15 - 08h50
09h00 - 10h00

Highlights Neuro-Oncology

Incontro clinico-patologico
Oncolunch

Prof. Dr. med. Nicolaus Andratschke, Head Doctor, Deputy Clinic Director, Department of Radiation Oncology, University Hospital Zurich USZ, Switzerland

Prof. Dr. med. Andreas Hottinger, MD, PhD, Director Brain & Spine Tumor Center, Director Lundin & Family Brain Tumor Research Center, Neuro-oncology, Departement of Clinical Neurosciences, Centre Hospitalier Universitaire Vaudois CHUV, Lausanne, Switzerland

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

Si ringraziano gli sponsor:

abbvie

AMGEN
Oncology

astellas

AstraZeneca

BAYER

BeiGene

Bristol Myers Squibb

Debiopharm
BY DEVELOP FOR PATIENTS

deciphera

Eisai

hvc
human health care

Lilly

GILEAD

GSK

Incyte

IPSEN
Innovation for patient care

JANSSEN
PHARMACEUTICAL COMPANIES
or Johnson & Johnson

MERCK

MSD
INVENTING FOR LIFE

Pfizer

NOVARTIS | Reimagining Medicine

Pharma
Mar

Roche

sanofi

Seagen

Takeda



Programma sempre
aggiornato su
www.eoc.ch/formazioni

Istituto Oncologico della Svizzera Italiana

Oncolunch & Revisione Blau-Rotbuch IOSI 2023

Gli eventi si terranno in modalità online webinar e in presenza all'Auditorium dell'Ospedale Regionale di Bellinzona e Valli - Bellinzona.

5 aprile

08h15 - 08h50
09h00 - 10h00

Highlights Lung Tumors

Incontro clinico-patologico
Oncolunch

Prof. Dr. med. Alfredo Addeo, Head of Oncology Division, Hôpitaux Universitaires Genève HUG, Geneva, Switzerland

Prof. Dr. med. Matthias Guckenberger, Head Doctor, Department of Radiation Oncology, Director Comprehensive Cancer Center Zurich, University Hospital Zurich USZ, Switzerland

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

3 maggio

08h15 - 08h50
09h00 - 10h00

Highlights Urogenital Tumors

Incontro clinico-patologico
Oncolunch

Prof. Thomas Powles, Professor of Genitourinary Oncology, Director Barts Cancer Centre at St. Bartholomew's Hospital, Lead for Solid Tumour Research London, United Kingdom

Prof. Ananya Choudhury, Chair and Honorary Consultant in Clinical Oncology, Co-Group Leader Translational Radiobiology, The University of Manchester, United Kingdom

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

14 giugno

08h15 - 08h50
09h00 - 10h00

Highlights Melanoma

Incontro clinico-patologico
Oncolunch

Prof. Paolo A. Ascierto, National Tumour Institute "Fondazione G. Pascale" Unit of Melanoma, Cancer Immunotherapy and Innovative therapy, Naples, Italy

Dr. med. Andrea Maurichi, Melanoma and Ocular Tumor Surgical Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

Si ringraziano gli sponsor:

abbvie

AMGEN
Oncology

astellas

AstraZeneca

BAYER

BeiGene

Bristol Myers Squibb

Debiopharm
WE DEVELOP FOR PATIENTS

deciphera

Eisai
human health care

Lilly

GILEAD

GSK

Incyte

IPSEN
Innovation for patient care

JANSSEN
PHARMACEUTICAL COMPANIES
of Johnson & Johnson

MERCK

MSD
INVENTING FOR LIFE

Pfizer

NOVARTIS | Reimagining Medicine

Pharma Mar

Roche

sanofi

Seagen

Takeda



Programma sempre
aggiornato su
www.eoc.ch/formazioni

Istituto Oncologico della Svizzera Italiana

Oncolunch & Revisione Blau-Rotbuch IOSI 2023

Gli eventi si terranno in modalità online webinar e in presenza all'Auditorium dell'Ospedale Regionale di Bellinzona e Valli - Bellinzona.

6 settembre

08h15 - 08h50
09h00 - 10h00

Highlights Breast Cancer

Incontro clinico-patologico
Oncolunch

Prof. Grazia Arpino, Professor of Medical Oncology, Department of Clinical Medicine and Surgery, Università degli Studi di Napoli Federico II in Naples, Italy

Dott. Oreste Davide Gentilini, Chairman of EUBREAST Italy ETS; Head of Breast Surgery, San Raffaele University and Research Hospital in Milan, Italy

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

4 ottobre

08h15 - 08h50
09h00 - 10h00

Highlights Lymphomas + Myeloma

Incontro clinico-patologico
Oncolunch

Dr.ssa Francesca Maria Gay, MD, PhD, Associate Professor, Department of Molecular Biotechnology and Health Sciences at the University of Turin; SSD Clinical trials in onco-ematology and multiple myeloma, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza in Turin, Italy

Dr. Andrés José María Ferreri, Oncologist and Head of the Clinical Research Unit on Lymphomas, Hematology and Bone Marrow Transplantation Unit of the IRCCS San Raffaele Hospital in Milan, Italy

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

8 novembre

08h15 - 08h50
09h00 - 10h00

Highlights Gastrointestinal Tumors

Incontro clinico-patologico
Oncolunch

Prof. Dr. Andrea Sartore Bianchi, Director S.S. Molecular Clinical Oncology, S.C. Falck Oncology; Department of Hematology, Oncology and Molecular Medicine, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy

Dr.ssa Rebecca Muirhead, Honorary Senior Clinical Researcher, Department of Oncology, University of Oxford, United Kingdom

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

Si ringraziano gli sponsor:

abbvie

AMGEN
Oncology

astellas

AstraZeneca

BAYER

BeiGene

Bristol Myers Squibb

Debiopharm
WE DEVELOP FOR PATIENTS

deciphera

Eisai

hbc
human health care

Lilly

GILEAD

GSK

Incyte

IPSEN
Innovation for patient care

JANSSEN
PHARMACEUTICAL COMPANIES
or Johnson & Johnson

MERCK

MSD
INVENTING FOR LIFE

Pfizer

NOVARTIS | Reimagining Medicine

Pharma
Mar

Roche

sanofi

Seagen

Takeda



Programma sempre
aggiornato su
www.eoc.ch/formazioni

Istituto Oncologico della Svizzera Italiana

Oncolunch & Revisione Blau-Rotbuch IOSI 2023

Gli eventi si terranno in modalità online webinar e in presenza all'Auditorium dell'Ospedale Regionale di Bellinzona e Valli - Bellinzona.

6 dicembre

08h15 - 08h50
09h00 - 10h00

Highlights Gynecological Tumors

Incontro clinico-patologico
Oncolunch

Dr.ssa Ana Oaknin, MD PhD, Head of Gynaecological Cancer Program, Medical Oncology Department, Vall D'Hebron University Hospital and Institute of Oncology in Barcelona, Spain

Dr.ssa Domenica Lorusso, Associate Professor of Obstetrics and Gynecology at the Catholic University of Rome and Responsible for Clinical Research at Fondazione Policlinico Gemelli IRCCS, Rome, Italy

10h30 - 11h30
11h30 - 12h30

Revisione Blau-Rotbuch 2023, linee guida IOSI
"Meet the Professor"

Si ringraziano gli sponsor:

abbvie

AMGEN
Oncology

astellas

AstraZeneca

BAYER

BeiGene

Bristol Myers Squibb

Debiopharm
WE DEVELOP FOR PATIENTS

deciphera

Eisai

hbc
human health care

Lilly

GILEAD

GSK

Incyte

IPSEN
Innovation for patient care

janssen
PHARMACEUTICAL COMPANIES
or Johnson & Johnson

MERCK

MSD
INVENTING FOR LIFE

Pfizer

NOVARTIS | Reimagining Medicine

Pharma
Mar

Roche

sanofi

Seagen

Takeda